Already on a GLP-1 medication? This monitoring blood test tracks your metabolic response, liver and kidney function, thyroid health, and inflammation to keep your progress on track.
Your results delivered as a complete pathology report, with reference ranges and clinical context for every marker. Easy to read yourself or hand straight to your GP.
The same pathology report format used by hospitals and GPs across Australia.
Every result is shown alongside the normal range. Abnormal results are highlighted in red so you spot them straight away.
Delivered privately within 24-48 hours of testing. Yours to keep, share or print.
See at a glance which markers are healthy and which need attention.
Calculated free testosterone is below the lower reference limit. May be associated with symptoms of low testosterone including fatigue, low libido, and reduced energy.
Metabolic, cardiovascular, organ, thyroid and inflammation markers measured together. Reveals whether GLP-1 is producing the metabolic improvements you expect AND catches the side effects that need monitoring.
The most accurate way to track GLP-1 efficacy. HOMA-IR should drop significantly within 3-6 months on treatment. If it is not, dose adjustment or alternative approach may be needed. Beyond scale weight, this is the real progress metric.
Weight loss is one signal. HbA1c improvement is the actual metabolic health change. A drop of 0.5-1.0%+ on GLP-1 over 3 months is typical and shows the medication is improving how your body handles blood sugar.
GLP-1 medications carry a black-box warning for medullary thyroid cancer risk. Routine thyroid monitoring on treatment is standard care. TSH, FT3 and FT4 together reveal subclinical thyroid dysfunction the standard TSH check alone would miss.
Weight loss should reduce inflammation. hsCRP catches the low-grade inflammation that drives cardiovascular disease and metabolic dysfunction. Tracking it on GLP-1 reveals whether the metabolic benefits are translating to lower inflammation.
ALT, AST, ALP, GGT, eGFR, creatinine and electrolytes. The organ-stress markers most likely to shift on GLP-1 medication. Regular monitoring catches issues early enough to adjust treatment before harm occurs.
Australia's easiest blood test
Step one
Order your blood test
Choose from 200+ blood tests or build your own. Once purchased, you'll get an instant pathology request form delivered to your inbox as a PDF, ready for use.
Instant pathology request formStep two
Walk in to collect your sample
Take your pathology request form to any of our 3,300+ partner collection centres across Australia. No need to book, just walk in and get your sample collected.
3,300+ collection centresStep three
Receive your results
Your results are reviewed by our AHPRA-registered doctors and sent privately to your email or SMS, usually within 24-48 hours.
Results in 24-48 hoursThousands of Aussies trust MediTests to make blood testing fast, easy and stress-free.
No blood test ever refused
Whether you're tracking symptoms or just want peace of mind, you're in control. Order any test you like, no doctor's approval needed.
You'll know exactly where you stand.
No blood test ever refused. Order any panel without a referral or a reason
200+ blood tests available to order online
Get your results in 24-48 hours
Original lab report from a NATA accredited laboratory
All pricing includes referral, testing and results. No hidden fees.
Everything you need to know before you order.
Order your test online today. No consult or referral required, no waiting room, no hidden fees. Results in 24 to 48 hours.
Hundreds of Australians have skipped the gatekeeping and wait, and taken control of their health with MediTests.
Once you are taking a GLP-1 medication, regular blood testing helps ensure your body is responding as expected and that no adverse changes are developing. This panel builds on the pre-treatment baseline by adding thyroid function and high sensitivity CRP, two markers that become particularly relevant during active GLP-1 therapy.
Thyroid monitoring is a sensible precaution during GLP-1 use given the known interaction between GLP-1 receptors and thyroid tissue. hsCRP provides a measure of systemic inflammation, which often improves alongside metabolic changes but can also signal early complications if it remains elevated. Together with glucose, insulin, lipid, liver, and kidney markers, this panel gives a thorough picture of how your body is tolerating and responding to treatment.
This panel is suitable for use approximately 3 months after starting GLP-1 therapy and can be repeated at regular intervals as recommended by your healthcare provider. It does not replace clinical review but gives you the data needed to have more informed conversations with your doctor.
Fasting Glucose: Measures blood sugar levels after fasting. Used to track whether glucose control is improving during treatment.
Fasting Insulin: Reflects insulin production at rest. Monitoring changes in fasting insulin during treatment can indicate whether insulin resistance is improving.
HOMA-IR Score: A calculated estimate of insulin resistance derived from fasting glucose and insulin. Useful for tracking metabolic improvement over time.
HbA1c: Reflects average blood glucose over the past two to three months. A key marker for monitoring glucose control during GLP-1 therapy.
Total Cholesterol: A broad measure of cardiovascular risk tracked alongside other lipid markers to assess treatment-related changes.
LDL Cholesterol: The cholesterol fraction most associated with cardiovascular risk. Monitored during treatment to track any lipid changes.
HDL Cholesterol: The protective cholesterol fraction. An increase in HDL during treatment is a positive metabolic indicator.
Triglycerides: Elevated triglycerides are common in people with insulin resistance and often improve with GLP-1 therapy. Tracked to monitor metabolic response.
Non-HDL Cholesterol: A more complete measure of cardiovascular risk than LDL alone, calculated by subtracting HDL from total cholesterol.
Bilirubin: A waste product from red blood cell breakdown. Monitored as part of ongoing liver health assessment during treatment.
Direct Bilirubin: Provides more specific information about liver and bile duct function when total bilirubin is elevated.
ALP (Alkaline Phosphatase): A liver and bone enzyme. Ongoing monitoring detects any treatment-related changes in liver health.
AST (Aspartate Aminotransferase): A marker of liver cell integrity. Assessed alongside ALT to identify any liver stress during treatment.
ALT (Alanine Aminotransferase): One of the most sensitive markers of liver cell damage. Important to monitor during medication use.
GGT (Gamma-Glutamyl Transferase): Sensitive to liver stress and medication effects. Tracked as part of routine liver function monitoring.
Albumin: Produced by the liver and reflects both liver function and nutritional status. Monitored during treatment as appetite changes may affect protein intake.
Globulin: Assessed alongside albumin to characterise liver function and identify inflammatory patterns.
Total Protein: A combined measure of albumin and globulin providing a broad assessment of liver function and nutritional status.
Sodium: An essential electrolyte for fluid balance and blood pressure regulation. Monitored as part of ongoing kidney and metabolic health assessment.
Potassium: Critical for heart rhythm and muscle function. Abnormal levels can have significant cardiac implications.
Chloride: Works alongside sodium to maintain fluid and acid-base balance. Assessed as part of a complete electrolyte profile.
Bicarbonate: Reflects the kidneys’ ability to regulate blood pH. A marker of metabolic and renal health.
Urea: A kidney-filtered waste product. Elevated levels can indicate reduced kidney function or changes in dietary protein intake.
Creatinine: One of the most reliable markers of kidney function. Monitored during treatment to detect any renal changes.
eGFR (Estimated Glomerular Filtration Rate): The best overall indicator of kidney filtration capacity. Tracked to identify any early decline in kidney function.
TSH (Thyroid Stimulating Hormone): The most sensitive indicator of thyroid function. Included given the known interaction between GLP-1 receptors and thyroid tissue. Abnormal TSH can affect metabolism, energy, and weight regulation.
FT4 (Free Thyroxine): The primary hormone produced by the thyroid. Assessed alongside TSH to provide a more complete picture of thyroid function.
FT3 (Free Triiodothyronine): The active form of thyroid hormone with a direct effect on cellular metabolism. Measured alongside FT4 and TSH to assess how well the body is converting thyroid hormones.
High Sensitivity CRP (hsCRP): A sensitive marker of low-grade systemic inflammation. Tracking hsCRP during therapy helps identify whether inflammation is improving in line with metabolic changes or flagging early concerns.
1. Receive your referral instantly after purchase
2. Quick blood test at your local collection centre
3. Results to your inbox within 1-2 days
